ORACLERecruiting

ORACLE: Observation of Residual Cancer Using Liquid Biopsy Evaluation

Gender
Women and men
Age
18 years and older
Trial type
Observational
Line of therapy
Relapsed / refractory
Phase
—

What is this trial about?

For many types of cancer in the early stages, treatment is initially aimed at a cure. Nevertheless, the disease can return () even after initially successful treatment. New methods are being developed to improve the early detection of potential recurrences. The ORACLE study is investigating whether a novel blood test for (ctDNA) can reliably detect a cancer recurrence earlier than current standard examinations. Patients aged 18 and older who have been treated for early-stage solid cancers, such as bladder cancer, , breast cancer, skin cancer (), , stomach cancer, pancreatic cancer, head and neck tumors, ovarian cancer, uterine cancer, kidney cancer, colon cancer, or rectal cancer, are eligible to participate in this study.

Trial flow

Requirements

Diagnosis: invasive bladder/upper urinary tract carcinoma, NSCLC, breast cancer, cutaneous melanoma, esophageal carcinoma, gastroesophageal junction carcinoma, gastric adenocarcinoma, pancreatic adenocarcinoma, squamous cell carcinoma of the head and neck, epithelial ovarian/Fallopian tube carcinoma, endometrial cancer, and renal cell carcinoma (RCC)

Age: 18 years and older

Line of therapy: Rezidiv / primär refraktär

Key inclusion criteria: curative approach

Allocation

Stratifizierung anhand von Markern

Treatment

Guardant Reveal: blood test for use in recurrence detection of early-stage solid tumorsone cohort for each type of tumor: invasive bladder/upper urinary tract carcinoma, NSCLC, breast cancer, cutaneous melanoma, esophageal carcinoma, gastroesophageal junction carcinoma, gastric adenocarcinoma, pancreatic adenocarcinoma, squamous cell carcinoma of the head and neck, epithelial ovarian/Fallopian tube carcinoma, endometrial cancer, and renal cell carcinoma (RCC)

Follow-up

36 months

Detailed description

When cancer cells grow or die, they release small fragments of their genetic material into the bloodstream. These fragments are known as circulating tumor DNA (ctDNA). Using a procedure called a —a minimally invasive blood test—the blood can be specifically screened for these tumor DNA fragments without the need for a tissue . The ORACLE study uses a specialized ctDNA test (Guardant Reveal) designed to detect even the smallest remaining traces of tumor or cancer cells in the body (, MRD) after cancer treatment has been completed. The presence of ctDNA in the blood after treatment may indicate an increased risk of cancer recurrence.

The goal of this is to investigate whether this blood test can reliably detect a relapse earlier than standard imaging procedures and clinical examinations. This is an observational study in which no new treatment is being tested. Patients’ regular follow-up care and treatment will remain unchanged. The only difference is that additional blood samples will be taken and tested for ctDNA. The results of the blood test will not influence further treatment. The study includes twelve different for various tumor types. These include, among others, muscle-invasive bladder cancer (including ureteral and renal pelvic cancer), non-small-cell lung cancer, breast cancer with various receptor characteristics (-positive, , or -positive/HER2-negative), cutaneous melanoma, esophageal and gastric cancer, pancreatic cancer, squamous cell carcinoma of the head and neck, ovarian and fallopian tube cancer, uterine cancer, , and . Blood samples will be collected over a period of up to three years. The main objective () of the study is to evaluate the distant recurrence-free interval (D-RFi), that is, the time until the occurrence of a recurrence with distant metastases (spread of the cancer beyond the originally affected organ). In addition, the study will examine how reliable the test is and how far in advance it can indicate a recurrence (lead time). The study does not test a new drug and has no impact on the patients’ treatment.

Patients aged 18 and older who have been treated for early-stage cancer with the goal of a cure (curative treatment) are eligible to participate in the study. A prerequisite is that there are no known distant metastases at the time of enrollment and that patients are able to participate in regular follow-up examinations. In addition, they must be willing to provide regular blood samples over an extended period of time.

Facts

  1. Type of disease: various
  2. Cancer characteristics: treated with the intent to cure (curative), early stage (depending on tumor type)
  3. What the study investigates: whether a blood test for (ctDNA) can reliably detect a cancer earlier than current standard care
  4. Study objective: To evaluate the clinical utility of a ctDNA test for detecting cancer recurrences
  5. Study duration: up to three years (regular blood draws as part of routine follow-up care)
  6. Study characteristics: , , twelve , no change in treatment, blood draws over up to three years

Trial sites

3 trial sites in Germany are listed.

  • Asklepios Klinik Altona

    Paul-Ehrlich-Straße 1, 22763 Hamburg

    Recruiting
  • SLK-Kliniken Heilbronn GmbH

    74078 Heilbronn

    Recruiting
  • LMU Klinikum

    81377 München

    Recruiting

This list is compiled to the best of our knowledge but without guarantee: it may be incomplete, and a site's recruitment status can change at any time. Last checked against the trial registers on .

Medical editorial team

  • Dr. med. Sebastian SommerSpecialist in internal medicine with a focus on hematology and oncology
  • PD Dr. med. Matthias FröhlichSpecialist in internal medicine, immunology and emergency medicine

This description is based on the public trial registry entry and was translated into plain language by our medical editorial team. Whether participation is an option for you is a decision you make together with your treating physician.